Enoxaparin Dosing Guidelines

Standard Therapeutic Dosing

• The American Heart Association recommends a therapeutic dose of 1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism and acute coronary syndromes, with equivalent or superior efficacy compared to unfractionated heparin 1, 2, 3.
• For acute coronary syndrome, the American College of Cardiology suggests a 30 mg intravenous bolus may be given initially, followed by 1 mg/kg subcutaneously every 12 hours 2, 5.

Prophylactic Dosing

• The standard dose for VTE prophylaxis is 40 mg subcutaneously once daily, according to clinical guidelines 4, 6.

Critical Dose Adjustments

Severe Renal Impairment

• In patients with creatinine clearance <30 mL/min, the dose should be reduced to 1 mg/kg subcutaneously once daily to avoid increased bleeding risk, as recommended by the National Comprehensive Cancer Network 7.

Elderly Patients

• For patients ≥75 years receiving fibrinolytic therapy, enoxaparin should not be used due to increased bleeding risk, as advised by the American College of Cardiology 5.

Low Body Weight

• For patients <50 kg, specific institutional dosing algorithms should be developed to avoid excessive anticoagulation, according to the National Comprehensive Cancer Network 7.

Special Clinical Contexts

Cancer-Associated VTE

• Dalteparin is preferred over enoxaparin for cancer-associated VTE, but if enoxaparin is used, it should be dosed at 1 mg/kg every 12 hours, as recommended by the National Comprehensive Cancer Network 7.

Monitoring and Safety

• Routine anti-Xa monitoring is not required for standard dosing but should be considered in severe renal failure, pregnancy, and obesity, according to the European Heart Association 3.
• Platelet count monitoring is necessary during treatment to detect heparin-induced thrombocytopenia, as recommended by the American College of Cardiology 5.